PATIENT PROFILES
The Mayo Score is used to assess the severity of ulcerative colitis
The Mayo Score consists of 4 factors1:
The Mayo Score ranges from 0-12, with higher scores indicating
more severe disease.
Demonstrating an effect on a composite multiple clinical
factor measure does not represent a clear effect on any of the
individual components.
Bio-naïve moderate ulcerative colitis
Devin, 28
Elementary school teacher
At first, Devin thought his symptoms were caused by nerves from starting out in his career, but they got worse over time. Devin shared with his GI that he likes using steroids because he doesn’t have to take them all the time.
Diagnosis:
Moderate ulcerative colitis
Mayo score 8
7 loose stools daily
Rectal bleeding with some stools
Time Since Diagnosis:
6 months
Imaging:
Colonoscopy showed disease-
marked erythema, absent vascular
pattern, friability, erosions.
Treatment History:
Devin is currently on steroids. Other
conventional therapies haven’t
provided relief.
Devin says he’s worried about the side effects of biologics. For patients like Devin, assess how informed they are about advanced therapies* and offer to review their safety profiles.
*Advanced therapies are used after failure of conventional therapies.
Bio-naïve severe ulcerative colitis
Corrine, 40
Accountant
Corrine has been living with ulcerative colitis for a long time and has developed coping strategies to work around her symptoms. Now that she’s working from home, running to the bathroom is more convenient than it used to be, but she’s frustrated that the treatments she has tried so far only work for the short term.
Diagnosis:
Severe ulcerative colitis
Mayo score 11
15 loose stools daily
Rectal bleeding with more
than half of stools
Disease Duration:
10 years
Imaging:
Repeat colonoscopy showed
spontaneous bleeding and
ulceration.
Treatment History:
Did not respond well to
immunosuppressants; recently
completed a course of steroids to
manage a flare.
Corrine wonders if infusions or injections would be a better fit for her. For patients like Corrine, consider asking if they’d prefer to self-administer their treatment or have it administered by a healthcare professional.
Consider which treatment you would
recommend for patients like Devin and
Corrine
The Crohn’s Disease Activity Index (CDAI) score is used to assess the severity of Crohn’s disease
The CDAI consists of 8 factors2:
CDAI scores range from 0 to ~600, with higher scores
indicating greater severity.3
Demonstrating an effect on a composite multiple clinical
factor measure does not represent a clear effect on any
of the individual components.
Bio-hesitant moderate Crohn's disease
Tina, 26
Software engineer
At 26, Tina started to experience abdominal pain and frequent bowel movements. She tried to manage her symptoms by eliminating certain foods from her diet, but her symptoms started to progress until she felt she couldn’t ignore them anymore.
Diagnosis:
Moderate Crohn’s disease
CDAI score 250
10 loose stools daily
Moderate abdominal pain
Time Since Diagnosis:
6 months
Type:
Ileocolitis
Imaging:
Colonoscopy revealed deep
inflammatory ulcers in the transverse
colon, sigmoid colon, and ileum.
Treatment History:
Conventional therapy, including 2
rounds of steroids, hasn’t provided
relief.
Tina has expressed concern about safety risks of advanced therapies.†
†Advanced therapies are used after failure of conventional therapies.
Steroid-dependent, bio-naïve moderate Crohn's disease
Mark, 22
Waiter
Mark has a fast-paced job in a busy restaurant, and he’s worried about missing work. He likes that steroids provide him relief.
Diagnosis:
Moderate Crohn’s disease
CDAI score 280
8 loose stools daily
Severe abdominal pain
Below ideal body weight
Disease Duration:
3 years
Type:
Ileitis
Imaging:
CT enterography of terminal ileum
shows irregularity, nodularity, wall
thickening, and narrowed lumen.
Treatment History:
Conventional therapy and anti-
diarrheals have provided partial
relief.
Mark wants a therapy he doesn’t have to take every day.
Consider which treatment you would
recommend for patients like Tina and Mark
Explore more topics
Here to support your patients
Once you prescribe ENTYVIO, EntyvioConnect offers a range of
programs designed to help your patients in the way they need it
most.
Learn about starting and maintaining treatment
What do the experts have to
say?
The content on this page has been written and
reviewed by Takeda.
IMPORTANT SAFETY INFORMATION
Contraindications
WARNINGS AND PRECAUTIONS
IMPORTANT SAFETY INFORMATION
Contraindications
ENTYVIO is contraindicated in patients who have had a known serious or severe hypersensitivity reaction to ENTYVIO or any of its excipients.
Warnings and precautions
Adverse reactions
The most common adverse reactions (incidence ≥3% and ≥1% higher than placebo) were: nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, and injection site reactions with subcutaneous administration.
Drug interactions
Because of the potential for increased risk of PML and other infections, avoid the concomitant use of ENTYVIO with natalizumab products and with TNF blockers.
INDICATIONS
Adult Ulcerative Colitis (UC):
ENTYVIO is indicated in adults for the treatment of moderately to severely active UC.
Adult Crohn’s Disease (CD):
ENTYVIO is indicated in adults for the treatment of moderately to severely active CD.
Dosage forms & strengths:
Please click for Full Prescribing Information.
References: